FOXO4-DRI

Overview

FOXO4-DRI is a research-grade peptide compound that supports laboratory investigation into the pathways outlined in current literature. The focus keyword, buy FOXO4-DRI research peptide, is integrated here because investigators often search by compound name, format, and analytical standard when comparing suppliers.

FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells, triggering apoptosis selectively in senescent cells. Published research demonstrated restoration of physical fitness, fur density, and renal function in fast-aged mice. Research applications include cellular senescence biology and senolytic strategy evaluation. Molecular weight: approximately 1,600 Da.

Within the Lab of Peptides catalogue, FOXO4-DRI is grouped alongside Thymosin Alpha-1 and Epitalon and anchored within Longevity Immune Support peptides. This helps researchers move from compound-specific review into broader pathway comparison without leaving the core research archive.

Research Background

FOXO4-DRI entered the literature because its molecular design aligned with a defined biological question. Early programmes, institutional studies, and preclinical model work examined how the compound class might influence receptor signalling, cellular adaptation, or tissue-level response patterns under controlled conditions.

Research background matters because peptide handling, sequence stability, and route-specific formulation all affect interpretation. For that reason, technical sourcing decisions often include purity review, storage validation, and protocol matching to the underlying model rather than broad generalisation.

Researchers comparing FOXO4-DRI with Thymosin Alpha-1 often focus on mechanism contrast, assay endpoints, and formulation constraints. That is particularly relevant when different compounds occupy adjacent commercial keyword clusters but operate through different receptor or transcriptional pathways.

Mechanism of Action (Research Context)

FOXO4-DRI research generally centres on how the compound interacts with a specific receptor, pathway, or molecular target. FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells, triggering apoptosis selectively in senescent cells. Published research demonstrated restoration of physical fitness, fur density, and renal function in fast-aged mice. Research applications include cellular senescence biology and senolytic strategy evaluation. Molecular weight: approximately 1,600 Da.

Studies suggest that mechanistic interpretation is strongest when exposure time, formulation state, and control selection are kept constant. In vitro studies show that downstream markers can vary sharply across cell type and tissue context, which is why reproducible sourcing and storage matter at the procurement stage.

Data indicates that investigators using FOXO4-DRI in the same research program as Thymosin Alpha-1 or Epitalon often do so to compare signalling breadth, tissue selectivity, or pathway overlap. These links support internal navigation for compound comparison rather than consumer-style recommendation.

Research Applications

• FOXO4-DRI for sale pathway mapping in controlled research models
• Receptor or signalling cascade comparison against adjacent peptide compounds
• Formulation and storage-dependent stability assessment in assay workflows
• In vitro and in vivo experimental design requiring 99%+ HPLC-verified material
• Category-level review using linked reference compounds and related research posts

Compound Specifications

Quality Assurance

Certificate of Analysis (COA): Each batch of peptides supplied by Lab of Peptides is independently verified by third-party analytical laboratories. COA documents confirming 99%+ purity via HPLC analysis are available upon request. Contact our team at research@labofpeptides.com to request the COA for any specific product batch. Each batch is aligned to third-party analytical review, and Lab of Peptides maintains batch-level documentation practices to support researchers who require confirmation before beginning a new protocol cycle.

Research Use Only Disclaimer: For Research Use Only. Not for Human Consumption. Not for Diagnostic or Therapeutic Use. This product has not been evaluated by the Food and Drug Administration. Intended exclusively for in vitro and in vivo scientific research by qualified professionals.

Frequently Asked Questions

buy FOXO4-DRI senolytic research peptide USA

FOXO4-DRI is used in research to study mechanism, signalling behaviour, and model-specific biological response under controlled laboratory conditions. Research framing remains essential because this catalogue is intended for scientific investigation only.

How is FOXO4-DRI supplied by Lab of Peptides?

FOXO4-DRI is supplied in lyophilized powder in sterile vial with third-party purity verification available through batch-level documentation. Related compounds such as Thymosin Alpha-1 and Epitalon can also be reviewed for protocol planning.

FOXO4 p53 peptide apoptosis research for sale

The reported molecular weight for FOXO4-DRI is approximately 1,600 Da, based on the research context provided for this catalogue entry.

Is FOXO4-DRI approved for human use?

Lab of Peptides supplies FOXO4-DRI exclusively for in vitro and in vivo scientific research. This compound is not approved by the FDA for human use and is not intended for human consumption or self-administration. For research use only.